WO2004016262A1 - アミノ酸含有チュアブル錠 - Google Patents
アミノ酸含有チュアブル錠 Download PDFInfo
- Publication number
- WO2004016262A1 WO2004016262A1 PCT/JP2003/010181 JP0310181W WO2004016262A1 WO 2004016262 A1 WO2004016262 A1 WO 2004016262A1 JP 0310181 W JP0310181 W JP 0310181W WO 2004016262 A1 WO2004016262 A1 WO 2004016262A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- tablet
- chewable tablet
- chewable
- mixture
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 126
- 210000000214 mouth Anatomy 0.000 claims abstract description 36
- 230000001737 promoting effect Effects 0.000 claims abstract description 20
- 239000003826 tablet Substances 0.000 claims description 154
- 229940024606 amino acid Drugs 0.000 claims description 129
- 239000007910 chewable tablet Substances 0.000 claims description 86
- 239000000203 mixture Substances 0.000 claims description 70
- 229940068682 chewable tablet Drugs 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 25
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 18
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 18
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 18
- 239000008187 granular material Substances 0.000 claims description 18
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 18
- 229960000310 isoleucine Drugs 0.000 claims description 18
- 150000005846 sugar alcohols Chemical class 0.000 claims description 15
- 150000001720 carbohydrates Chemical class 0.000 claims description 14
- 230000001055 chewing effect Effects 0.000 claims description 14
- 238000000748 compression moulding Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 9
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 9
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 239000002274 desiccant Substances 0.000 claims description 6
- 210000003296 saliva Anatomy 0.000 claims description 6
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 5
- 239000008109 sodium starch glycolate Substances 0.000 claims description 5
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 4
- 230000002797 proteolythic effect Effects 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 120
- -1 aliphatic amino acids Chemical class 0.000 description 31
- 239000000047 product Substances 0.000 description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 150000005693 branched-chain amino acids Chemical class 0.000 description 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 14
- 229930006000 Sucrose Natural products 0.000 description 14
- 235000014113 dietary fatty acids Nutrition 0.000 description 14
- 239000000194 fatty acid Substances 0.000 description 14
- 229930195729 fatty acid Natural products 0.000 description 14
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 14
- 229960004793 sucrose Drugs 0.000 description 14
- 239000005720 sucrose Substances 0.000 description 13
- 239000000314 lubricant Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 9
- 239000011230 binding agent Substances 0.000 description 8
- 229940105329 carboxymethylcellulose Drugs 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000004386 Erythritol Substances 0.000 description 7
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 7
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 235000015165 citric acid Nutrition 0.000 description 7
- 235000019414 erythritol Nutrition 0.000 description 7
- 229940009714 erythritol Drugs 0.000 description 7
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 239000000811 xylitol Substances 0.000 description 7
- 235000010447 xylitol Nutrition 0.000 description 7
- 229960002675 xylitol Drugs 0.000 description 7
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 6
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 235000009697 arginine Nutrition 0.000 description 6
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 6
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 5
- 239000004373 Pullulan Substances 0.000 description 5
- 229920001218 Pullulan Polymers 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 235000019423 pullulan Nutrition 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- 239000004474 valine Substances 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 239000000832 lactitol Substances 0.000 description 3
- 235000010448 lactitol Nutrition 0.000 description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 3
- 229960003451 lactitol Drugs 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241001440267 Cyclodes Species 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010070245 Foreign body Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- PNMUAGGSDZXTHX-BYPYZUCNSA-N Gly-Gln Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-BYPYZUCNSA-N 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- KSMRODHGGIIXDV-YFKPBYRVSA-N N-acetyl-L-glutamine Chemical compound CC(=O)N[C@H](C(O)=O)CCC(N)=O KSMRODHGGIIXDV-YFKPBYRVSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960005488 aceglutamide Drugs 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229940102187 disintegrating oral tablet Drugs 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- LMBMDLOSPKIWAP-UHFFFAOYSA-N embutramide Chemical compound OCCCC(=O)NCC(CC)(CC)C1=CC=CC(OC)=C1 LMBMDLOSPKIWAP-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019223 lemon-lime Nutrition 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 230000018984 mastication Effects 0.000 description 1
- 238000010077 mastication Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- WPPDXAHGCGPUPK-UHFFFAOYSA-N red 2 Chemical compound C1=CC=CC=C1C(C1=CC=CC=C11)=C(C=2C=3C4=CC=C5C6=CC=C7C8=C(C=9C=CC=CC=9)C9=CC=CC=C9C(C=9C=CC=CC=9)=C8C8=CC=C(C6=C87)C(C=35)=CC=2)C4=C1C1=CC=CC=C1 WPPDXAHGCGPUPK-UHFFFAOYSA-N 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention relates to a chewable tablet containing an amino acid, and more particularly, to an amino acid-containing chewable tablet having improved oral disintegration and a method for producing the same.
- Amino acid-containing chewable tablets which are capable of taking amino acids without drinking water, include a chewable tablet containing 20 to 30% by weight of an amino acid with respect to the weight of the tablet and using reduced maltose or dextrin as an excipient. Tablets are known. However, it is difficult to consume a large amount of amino acids at a time with such an amino acid content.
- amino acids can be taken quickly, but conventional amino acid-containing chewable tablets require power for chewing and have a foreign body sensation in the mouth after chewing, making it difficult to take during exercise and tableting.
- the moldability is poor and it is not possible to contain a sufficient amount of amino acids to perform functions suitable for sports use.
- the amino acid content of sports amino acid granules is about 2-3 g per package on average, whereas conventional chewable tablets are only about 0.1 g for large tablets with a tablet weight of about 1 g. It has an amino acid content of only 2 to 0.3 g, which makes it difficult to supplement amino acids for sports use with tablets.
- An object of the present invention is to provide an amino acid-containing chewable tablet that is easy to chew and can contain a large amount of amino acids as needed.
- the present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result, by improving the oral disintegration properties of amino acid-containing tablets, it is possible to chew with a weak chewing force even during intense exercise,
- the present inventors have found that it is possible to make a soft chewable tablet without a foreign-body sensation and that it is possible to incorporate a large amount of amino acids into the chewable tablet, and have further studied to complete the present invention. That is, the present invention
- composition as described in (1) or (1) above, wherein the composition contains an oral disintegration promoting component.
- a chewable tablet comprising an amino acid and an oral disintegration promoting component
- a method for producing a rapidly disintegrating oral tablet in the oral cavity comprising compression-molding a powder containing an amino acid and an oral disintegration promoting component,
- the granules further contain sugar or Z and sugar alcohol
- the amino acid used in the present invention may be any one of one or a combination of two or more pure amino acids obtained by a fermentation method, a synthesis method or a plant extraction method, or a decomposed mixture of proteins such as whey protein or soy protein. Or a combination of a pure amino acid and a proteolytic mixture as appropriate.
- pure amino acids include, for example, aliphatic amino acids such as glycine and alanine, for example, branched-chain amino acids such as valine, leucine and isoleucine, for example, hydroxy amino acids such as serine and threonine, for example, asparaginic acid, glutamic acid, and the like.
- Acidic amino acids for example, amides such as asparagine and glutamine; for example, basic amino acids such as lysine, hydroxylysine, arginine, and ordinine; for example, sulfur-containing amino acids such as cystine, cystine, and methionine; for example, phenylalanine And aromatic amino acids such as tyrosine; for example, heterocyclic amino acids such as tributane and histidine; for example, cyclic amino acids such as proline and 4-hydroxyproline; and the like in the chewable tablet of the present invention.
- amino acid derivatives include, for example, acetyl glutamine, acetyl cysteine, quinone, 5-hydroxyproline, daltathione, creatine, S-adenylmethionine, glycylglycine, glycylglutamine, DOPA (dihydroxyfuramine). Enylalanine), aralanylglutamine, carnitine and the like.
- the amino acid used in the present invention may be a salt, and examples of such a salt include salts with organic or inorganic acids such as hydrochloride, sulfate, acetate, and the like, sodium salt, potassium salt, and the like. And salts with bases.
- the amino acid is one selected from branched-chain amino acids such as palin, leucine and isoleucine, amides such as asparagine and glutamine, basic amino acids such as lysine, hydroxylysine and arginine, and cyclic amino acids such as proline.
- branched-chain amino acids such as palin, leucine and isoleucine
- amides such as asparagine and glutamine
- basic amino acids such as lysine, hydroxylysine and arginine
- cyclic amino acids such as proline.
- a combination of two or more kinds is preferable, and more preferably, a combination of one or more kinds selected from a branched-chain amino acid such as valine, leucine and isoleucine and an amide such as asparagine and glutamine is exemplified.
- the combination of one or more amino acids includes, for example, a combination of three types of branched-chain amino acids consisting of palin, leucine and isoleucine (hereinafter, referred to as a composition of three types of branched-chain amino acids).
- the composition of the three types of branched-chain amino acids used is such that the ratio of palin, leucine, and isoleucine is 0.8-1.2: 1.3-2.5: 0.8-1.2.
- Glutamine may be used alone or in combination with one or more of the above-mentioned one or more branched-chain amino acids. 0.1 to 5 times the composition of the combination of the above.
- compositions in which arginine is used alone or in combination with glutamine or dalamine and the above-mentioned one or more kinds of branched-chain amino acids compositions in which arginine is used in combination with the above-mentioned one or more kinds of branched-chain amino acids, and the like. More specifically, a composition in which the above three kinds of branched chain amino acids are combined and a composition in which glutamine is mixed in a ratio of 1: 0.1 to 5 are further combined with a composition in which the above three kinds of branched chain amino acids are combined. 1 to 5 times the amount of the above three types of branched-chain amino acids Arginine 0.1 to 5 times that of the above composition.
- the chewable tablet containing the amino acid of the present invention and having improved oral disintegration or the orally disintegrable chewable tablet containing the amino acid preferably contains about 1 to 85% by weight of the amino acid, and 35 to 50% by weight. 80% by weight is more preferred.
- amino acids are more preferably contained in an amount of about 30 to 85% by weight, more preferably about 35 to 70% by weight, and particularly preferably 40 to 65% by weight. It is good to let.
- the average particle size of the amino acid is not particularly limited, but is preferably 200 m or less, more preferably 100 zm or less, and particularly preferably 50 m or less.
- improving the disintegration property in the oral cavity means, for example, that the time required for the tablet to disintegrate in the oral cavity only with saliva without chewing or the time required for the tablet to disintegrate in the mouth after chewing than in the case of conventionally known chewable tablets. It refers to shortening, and rapid oral disintegration in the oral cavity is, for example, longer than in the case of conventionally known chewable tablets, the time when the tablet disintegrates in the oral cavity only with saliva without chewing or the tablet disintegrates in the mouth after chewing It means that the time is getting shorter, and it is necessary to improve the taking ability.
- Means for improving the disintegration property in the oral cavity or means for imparting disintegration property in the oral cavity include, for example, a method of adding an oral disintegration promoting component to a tablet.
- examples of the oral disintegration promoting component include carboxymethylcellulose, carboxymethylcellulose calcium, carboxymethylcellulose sodium, crospovidone, croscarmellose sodium, sodium starch glycolate, etc., and preferably carboxymethylcellulose.
- Calcium or sodium starch glycolate, particularly preferably carboxymethylcellulose, can be used alone or in combination.
- These rapidly disintegrating components in the oral cavity are amino acid particles or granules containing amino acids. It is preferable that they are simply mixed and used so as not to cover the surface of the polymer.
- the oral disintegration promoting component is used alone or in combination with the tablet weight, preferably in an amount of about 0.5 to 20% by weight, more preferably about 0.5 to 5% by weight, and still more preferably about 0.5 to 5% by weight. 0.5 to 2% by weight can be contained.
- the average particle size of the oral disintegration promoting component is not particularly limited, but is preferably 200 im or less, more preferably 100 ⁇ m or less, and particularly preferably 50 m or less.
- saccharides include, for example, monosaccharides, disaccharides, and the like, and more specifically, lactose, maltose, trehalose, and the like.
- sugar alcohols include mannitol, reduced maltose syrup, maltitol, maltol, lactitol, xylitol, sorbitol, erythritol and the like.
- the saccharide or sugar alcohol can be arbitrarily selected from one type or a combination of two or more types depending on the type, the mixing ratio, and the content of the amino acid.
- the saccharide or sugar alcohol is used alone or in combination, preferably about 15 to 99% by weight, more preferably about 15 to 60% by weight, and still more preferably about 20 to 40% by weight, based on the tablet weight. It can be contained.
- the average particle size of the saccharide is not particularly limited, but is preferably 200 m or less, more preferably 100 m or less, and particularly preferably 50 m or less.
- these saccharides are simply used as a mixture so as not to cover the surface of the amino acid particles or the granules containing the amino acid.
- a water-soluble sugar alcohol such as sorbitol, erythritol, xylitol, lactitol and the like is contained in an amount of preferably 15% or more, more preferably 20% or more, based on the weight of the tablet. Inner collapse is further improved.
- hygroscopic amino acids such as proline, glycine, arginine, and serine and sorbitol, erythritol, xylitol, Lacti
- proline glycine
- arginine arginine
- serine sorbitol
- erythritol erythritol
- xylitol xylitol
- Lacti hygroscopic amino acids such as proline, glycine, arginine, and serine and sorbitol, erythritol, xylitol, Lacti
- a binder, a lubricant, other additional components, and the like can be optionally contained in addition to the above-mentioned oral disintegration promoting component.
- the binder include polyvinylpyrrolidone, pullulan, acrylic acid-based polymer, polyvinyl alcohol, gelatin, agar, arabic gum, arabic gum powder, partially arsenic starch, macrogol, and the like. Two or more can be used if desired.
- the binder should preferably contain about 0.5 to 5% by weight, more preferably about 0.5 to 3% by weight, and more preferably about 0.5 to 2% by weight, based on the weight of the tablet. Can be.
- the binder can be used after being dissolved in an aqueous solution such as water.
- the average particle size of the binder is not particularly limited, but is preferably 200 m or less, more preferably 100 m or less, and particularly preferably 50 m or less.
- the lubricant examples include sucrose fatty acid ester, magnesium stearate, calcium stearate, sodium stearyl fumarate, talc, sodium lauryl sulfate, light silicic anhydride, hydrous silicon dioxide, sucrose fatty acid ester, and the like. One or more of them can be used as desired.
- the lubricant is preferably contained in an amount of about 0.05 to 10% by weight, more preferably about 0.1 to 5% by weight, and even more preferably about 0.1 to 3% by weight, based on the weight of the tablet. Can be.
- the average particle diameter of the lubricant is not particularly limited, but is preferably 200/2 m or less, more preferably 100 m or less, and particularly preferably 50 m or less.
- these lubricants are simply mixed and used so as not to cover the surface of the amino acid particles or the granules containing the amino acid.
- Other additives include carbohydrates such as dextrin, starch, and cyclode.
- Bitterness correctors such as kisstrin, carotene beesin, edible yellow 5, edible red 2, edible color such as edible blue 2, edible lake pigment, coloring agents such as bengalanaicin, vitamin E, ascorbic acid, vitamin B , Vitamins such as vitamin A and vitamin D or derivatives thereof, minerals such as sodium, aspartame, glucose, fructose, sucralose, stevia, saccharose, sweeteners such as sodium saccharin, somatin, and fine granules
- Anti-solidification agents such as oxidized caustic acid, calcium silicate, synthetic aluminum gaylate, and talc; blowing agents such as baking soda; acidulants such as citric acid, malic acid, and tartaric acid; flavors such as lemon, lemon lime, orange, and menthol; Cellulose or a derivative thereof, crystalline cellulose, microcrystalline cell mouth, and the like.
- the other additives should preferably contain about 0.01 to 5% by weight, more preferably about 0.1 to 3% by weight, and still more preferably about 0.1 to 1% by weight, based on the weight of the tablet. Can be.
- chewable tablets refer to preparations designed on the premise of chewing in the oral cavity, for example, chewable tablets.
- the chewable tablet preferably has a tablet diameter (diameter) of about 7 to 20 mm, more preferably about 9 to 17 mm, and still more preferably about 10 to 16 mm. About 300 mg to about 1.5 g, more preferably about 400 mg to lg, and still more preferably about 500 mg to 90 mg.
- the content of amino acids can be increased, and in that case, the weight of the tablet relative to the amino acid content can be reduced. Therefore, the thickness of the tablet with respect to the tablet diameter can be reduced.
- the thickness of the chewable tablet of the present invention is preferably 2 to 8 mm, more preferably 3 to 6 mm, and particularly preferably 3.5 to 5 mm.
- the chewable tablet of the present invention containing amino acids in an amount of 35 to 70% by weight, more preferably 40 to 65% by weight, having a thickness of 3 to 6 mm, more preferably 3.5 to 5mm, diameter 9 ⁇ 17mm, more preferably 10 ⁇ 16mm, into a portable rectangular parallelepiped container with inner wall height 9 ⁇ 18mm, length 48 ⁇ 72mm, width 30 ⁇ 5 Omm 24 tablets arranged side by side in 2 to 5 rows, inner wall height 40 to 7 Omm, vertical width 30 to 50 mm, portable width 9 to 30 mm max. Containing 8 to 60 tablets. At that time, a desiccant commonly used in foods may be allowed to coexist. Further, the desiccant and the
- the chewable tablet of the present invention is preferably softer than a general tablet, but preferably has a hardness of about 5 ON or more, more preferably about 6 ON or more, more preferably about 65 N or more, and most preferably about 65 N or more. 7 ON or more.
- the upper limit of tablet hardness is usually about 12 ON.
- the hardness is measured in the diameter direction of the tablet using a hardness meter (Type PTB-301) manufactured by Japan Machinery.
- the tablet disintegration time is preferably about 60 seconds to 150 seconds, more preferably about 50 seconds to 120 seconds, and even more preferably about 40 seconds to 100 seconds.
- the tablet disintegration time for each of the five healthy adults was measured by measuring the time required for the tablet to disintegrate with saliva alone after chewing with one tablet in the oral cavity, and the average value was shown. I have.
- the powder containing the amino acid and the oral disintegration promoting component may be, for example, the above-mentioned saccharide or Z and sugar alcohol, a binder, a lubricant or a normal additive in addition to the amino acid and the oral disintegration promoting component. It may contain other additive components used, for example, a bitterness corrector, a coloring agent, a sweetener, an acidulant, a flavor, etc., alone or in combination.
- a production method by compression-molding a powder containing an amino acid and an orally disintegrating ingredient can be mentioned.
- the compression molding method is not particularly limited, and a conventionally known method can be used.
- a conventional method of adding, mixing, and compression-molding a lubricant to a granular material containing various additive components such as an intraoral disintegration promoting component and an amino acid and a method in which a lubricant is previously applied to a punch surface, a mortar, and the like.
- a method of compressing and molding the powder after applying it to the wall may be used.
- the method for preparing such a compression molded product is not particularly limited.
- a direct tableting method in which various raw materials are mixed and compression molding, and a method in which the whole or a part of various raw materials is wet- or dry-granulated and then compression-molded.
- wet granulation examples include, for example, a method of adding a sugar or sugar alcohol to a powder containing an amino acid and an oral disintegration promoting component to form a mixture, adding water, and kneading and granulating. Thereafter, a tablet can be produced by adding a lubricant, an additive component, and the like, followed by compression molding.
- the water includes, for example, purified water, but is not particularly limited as long as it is acceptable under the Food Sanitation Law or the Pharmaceutical Affairs Law.
- saccharides, sugar alcohols, binders and the like can be added to water as required.
- the water content can be adjusted when water is added to the raw material components or a mixture thereof.
- the method of adding water is not particularly limited.
- the spraying method is not particularly limited as long as it is a spraying method usually used in the preparation process, but spray coating, spray drying, etc., more specifically, spraying using a fluidized bed granulator, spray dryer, etc.
- the used spraying etc. are mentioned.
- Mixtures containing water are usually kneaded before tableting.
- a method and an apparatus generally used as a tablet production means can be used. Further, it is preferable that the obtained tablet is further dried. Drying can be performed by any method generally used in the production of preparations, such as vacuum drying, freeze drying, air drying and the like.
- a stirring granulator for example, saccharides or sugar alcohols are added to a granule containing an amino acid and an oral disintegration promoting component to form a mixture.
- the powder can be compression-molded (a lubricant, an additive, etc. may be added at this time) to produce a tablet.
- the apparatus used for granulation is not particularly limited.
- a stirring granulator, a high-speed stirring granulator, a fluidized bed granulator / dryer, an extrusion granulator, a tumbling fluidized bed granulator / dryer and the like can be mentioned.
- the apparatus used for tableting is not particularly limited, and an apparatus generally used for tablet molding or granulation can be used.
- an apparatus generally used for tablet molding or granulation can be used.
- a rotary tableting machine, a single-tablet tableting machine, and the like can be used.
- the oral tablet disintegration time is shown as the average of five healthy adults, each containing one tablet in the oral cavity and measuring the time required for the tablet to disintegrate with saliva after chewing. .
- Example 2 compression molding was performed using a single-tally tableting machine (product name: AP-11 type, manufactured by Hata Iron Works) equipped with a flat punch with a diameter of 13 mm at a tableting pressure of 20 KN.
- the obtained tablet 1 has a tablet hardness of about 70 N,
- the tablet disintegration time in the oral cavity was about 90 seconds, and it was a tablet that was excellent in taking feeling as a chewable tablet.
- tableting troubles such as cabbing (C app ng) and sticking (Sticki ng) during the tableting process were not observed.
- tablettes were prepared by replacing mannitol of Example 1 with xylitol.
- the obtained tablet (hereinafter referred to as “tablet 2”) had a tablet hardness of about 75 N and a tablet disintegration time of about 115 seconds in the oral cavity, and was a tablet that was excellent in taking feeling as a chewable tablet. No tableting troubles such as capping (Stapping) and sticking (Steeking) during the tableting process were observed.
- a mixture of 1200 g of sized leucine, 600 g of isoleucine, 600 g of parin and 600 g of glutamine, an amino acid nutrient mixture, 5 g of xylitol 137, and 100 g of carboxymethylcellulose calcium was stirred using a stirring granulator ( Trade name: Vertical Granulator (VG-25, manufactured by Baurek) and mixed until a uniform mixture was obtained to obtain a mixture a.
- the purified water is charged into a stirring granulator (trade name: Vertical Granule Yule Ichiichi VG-25, manufactured by Pallek Co., Ltd.), and the mixture is kneaded and granulated for about 3 minutes together with the mixture a.
- Tablet 3 was a tablet hardness of about 71 N and a tablet disintegration time in the oral cavity of about 120 seconds, and was a tablet excellent in taking feeling as a chewable tablet. In addition, no tableting troubles such as cabbing (Cap ping) and statusing (Sticking) during the tableting process were observed.
- 1375 g of xylitol, 100 g of carboxymethylcellulose calcium, 100 g of carboxymethylcellulose, 350 g of citric acid and 125 g of fragrance are added to a mixture of amino acid nutrients consisting of 1200 g of sized leucine, 600 g of isoleucine, 60 Og of palin and 600 g of glutamine, and mixed. did.
- the obtained tablet 4 had a tablet hardness of about 81 N and a tablet disintegration time in the oral cavity of about 84 seconds, and was a tablet excellent in taking feeling as a chewable tablet. In addition, there were no tableting disorders such as cabbing (Capping) and statusing (Sticking) during the tableting process.
- a chewable tablet having a tablet weight of 833 mg (amino acid content of 50 Omg, amino acid content of about 60% by weight) was produced in the same manner as in Example 3 except that xylitol was replaced with reduced maltose syrup (hereinafter referred to as tablet 5). ).
- the obtained tablet 5 had a tablet hardness of about 68 N and a tablet disintegration time in the oral cavity of about 114 seconds, and was a tablet excellent in taking feeling as a chewable tablet.
- capping during the tableting process (Ca No tableting disorders such as PP ing) ⁇ sticking (Sticking) were observed.
- a fluidized bed of a mixture of 1200 g of sized leucine, 600 g of isoleucine, 600 g of phosphorus and 600 g of glutamine, an amino acid nutrient mixture, 137 g of trehalose, and 100 g of sodium starch glycolate The mixture was charged into a granulation dryer (Model WSG-5 manufactured by Glatt), and a binder solution obtained by dissolving 100 g of maltose and 50 g of pullulan in 1500 g of purified water was sprayed and then dried to obtain a granulated dried product.
- 40 g of sucrose fatty acid ester, 200 g of citric acid and 10 O.g of fragrance were added to 3660 g of the obtained granulated and dried product to obtain a tableting mixture.
- Stirred granulator prepared by mixing a nutrient mixture consisting of 1200 g of sized leucine, 600 g of isoleucine, 600 g of valine and 600 g of glutamine, 1375 g of erythritol, and 100 g of carboxymethylcellulose calcium.
- a nutrient mixture consisting of 1200 g of sized leucine, 600 g of isoleucine, 600 g of valine and 600 g of glutamine, 1375 g of erythritol, and 100 g of carboxymethylcellulose calcium.
- Purified water to which 50 g of pullulan was added was stirred with a granulator (trade name: Vertical Granule VG-25, manufactured by Pallek Co., Ltd.), kneaded and granulated for about 3 minutes together with the mixture b.
- the obtained granules are taken out of the granulator, and a fluidized-bed dryer (manufactured by Darat Corporation, It was dried for 20 minutes at a suction temperature of 80 ° C or less using WSG-5 type). 40 g of sucrose fatty acid ester and 100 g of fragrance were added to 3580 g of the obtained granulated and dried product to prepare a mixture for tableting.
- tablets 7 using a rotary tableting machine equipped with a flat punch with a diameter of 15 mm (product name: AP _15, manufactured by Hata Iron Works), compression molding at a tableting pressure of 20 KN, a tablet weight of 833 mg (amino acid Tuple tablets having a content of 500 mg and an amino acid content of about 60% by weight were manufactured (hereinafter referred to as tablets 7).
- the obtained tablet 7 had a tablet hardness of about 73 N and a tablet disintegration time of about 120 seconds in the oral cavity, and was a tablet excellent in taking feeling as a chewable tablet. No tableting troubles such as cabbing (Capping) and statusing (Sticking) during the tableting process were observed.
- a mixture of 1200 g of sieved leucine, 600 g of isoleucine, 600 g of phosphorus and 600 g of glutamine, a mixture of amino acid nutrients, 137 5 g of lactitol and 100 g of calcium carboxymethylcellulose was stirred by a granulator.
- a granulator (Trade name: Vertical Granule, One-Year-One VG-25, manufactured by Baurek), and mixed until a uniform mixture was obtained to obtain a mixture c.
- the purified water is charged into a stirring granulator (trade name: Vertical Granulator VG-25, manufactured by Baurek), and the mixture is kneaded and granulated for about 3 minutes together with the mixture c.
- the sample was taken out and dried using a fluid bed dryer (Model WSG-5, manufactured by Glatt) at an intake air temperature of 80 ° C or less for 20 minutes.
- a fluid bed dryer Model WSG-5, manufactured by Glatt
- sucrose fatty acid ester To 3580 g of the obtained granulated and dried product, 40 g of sucrose fatty acid ester, 280 g of citric acid and 100 g of flavor were added to obtain a mixture for tableting.
- a rotary tableting machine equipped with a 15 mm diameter flat punch (product name: AP One type 15 (manufactured by Hata Iron Works) was compression molded at a tableting pressure of 20 KN to produce tuple tablets with a tablet weight of 833 mg (amino acid content of 500 mg, amino acid content of about 60 wt%) (hereinafter referred to as tablets). 8).
- the obtained tablet 8 had a tablet hardness of about 65 N and a coagulant disintegration time in the oral cavity of about 120 seconds, and was a tablet excellent in taking feeling as a chewable tablet. No tableting troubles such as cabbing (Stapping) and sticking (Stinging) during the tableting process were observed.
- the purified water is charged into a stirring granulator (trade name: Vertical Granulator VG-25, manufactured by Pallek Co., Ltd.), kneaded and granulated for about 3 minutes together with the mixture d, and the obtained granulated product is granulated from the granulator.
- the sample was taken out and dried for 20 minutes at a suction temperature of 80 ° C or less using a fluidized-bed dryer (Model WSG-5, manufactured by Glatt).
- a fluidized-bed dryer Model WSG-5, manufactured by Glatt
- tablets 9 amino acid Tuple tablets having a content of 500 mg and an amino acid content of about 60% by weight were manufactured (hereinafter referred to as tablets 9).
- the obtained tablet 9 had a tablet hardness of about 71 N and a tablet disintegration time of about 120 seconds in the oral cavity, and was a tablet excellent in taking feeling as a chewable tablet.
- no tableting troubles such as cabbing (Cap ping) and statusing (Sticking) during the tableting process were observed.
- An agitated granulator was prepared by mixing a mixture of amino acid nutrients consisting of 1200 g of sized leucine, 600 g of isoleucine, 600 g of palin and 600 g of glutamine, 900 g of erythritol and 100 g of calcium carboxymethylcellulose.
- the obtained tablet 10 (a flat tablet having a diameter of 15 mm and a thickness of 4 mm) had a tablet hardness of about 75 N and a tablet disintegration time of about 115 seconds in the oral cavity, and was a tablet excellent in taking feeling as a chewable tablet. .
- tableting troubles such as cabbing (Cap pin) and sticking (Sticking) during the tableting process were not observed.
- An amino acid nutrient mixture consisting of 600 g of sized leucine, 300 g of isoleucine, 300 g of phosphorus, 300 g of Dalmin, and 2400 g of digest (Meiji Dairy) 900 g of carboxymethyl cellulose 100 g of Lulose Calcium was added to a stirring granulator (trade name: Perch Caldara Niyule Ichiichi VG-25, manufactured by Palek Co., Ltd.), and mixed until a uniform mixture was obtained. Thus, a mixture f was obtained.
- the tablet properties of tablets 1 to 11 obtained as described above were compared with known amino acid-containing chewable tablets.
- Known chewable tablets obtained by adding an emulsifier such as a sucrose fatty acid ester to 20% by weight of an amino acid such as a branched chain amino acid (a mixture of leucine, palin, and isoleucine in a ratio of 2: 1: 1 (by weight)) and 72% by weight of reduced maltose syrup a
- an emulsifier such as a sucrose fatty acid ester
- an amino acid such as a branched chain amino acid (a mixture of leucine, palin, and isoleucine in a ratio of 2: 1: 1 (by weight))
- 72% by weight of reduced maltose syrup a
- the tableting moldability was poor, and all tablets had scratches and chips due to sticking after molding.
- tablets 1 to 11 of the present invention in which the amino acid content of the chewable tablet a is tripled, have a stateing (S No damage to the tablet due to tieki ng) occurred.
- Chiwable tablets a have a disintegration time of 3 minutes or more in the oral cavity, and the feeling of ingestion is poor.
- the tablet of the present invention in which the amino acid content of chewable tablet b was doubled; In ⁇ 11, no tablet scratches etc. were caused by the cabbing (C app ng).
- the chewable tablet b left a foreign body feeling in the mouth after mastication, which is not preferable as a chewable tablet.
- the tablets 1 to 11 of the present invention dissolved rapidly in the mouth and gave a favorable texture.
- amino acids used for sports such as branched-chain amino acids and diets such as proline require about 2-3 g of replenishment at a time.
- chewable tablets a are large tablets with a tablet weight of 1 g, but contain only 20 Omg of amino acid and require 10 to 15 tablets to ingest the required amount. , Not practical.
- Chewable tablets b are large tablets containing 60 Omg of amino acids and measuring 2 cm in diameter and weighing 2 g, but the tablets are too large and inconvenient to carry.
- Tablet 3, Tablet 5, and Tablets 6 to 11 of the present invention can contain 500 mg of amino acid, and can exhibit their functions when taken at 5 to 6 tablets per day.
- the chewable tablet b weighs about 1Z3 and is highly portable.
- the tablet of the present invention did not discolor even after storage at 40 ° (for 3 months under humidified conditions), and there was no problem in stability. Extremely good preservation with less injuries. ⁇ Test Example 2>
- a tablet 10 (diameter 15 mm, thickness 4 mm, flat tablet) obtained in Example 10 was placed in a drawer-type portable small container having an inner wall height of 16 mm, a length of 56 mm, and a width of 34 mm, and a thickness of 7 mm. Twenty tablets (10 g amino acid total) were stored in two rows with a cylindrical desiccant with a diameter of 16 mm.
- Tablet 10 obtained in Example 10 (a flat tablet having a diameter of 15 mm and a thickness of 4 mm) was placed on a mobile phone having an inner wall height of 5 Omm and an elliptical bottom surface (an inner wall having a maximum length of 34 mm and a maximum width of 2 Omm).
- a desiccant thickness 7 mm, diameter 16 mm
- 12 tablets were stored.
- a chewable tablet containing an amino acid and having improved oral disintegration is provided.
- the chewable tablets can have a high amino acid content and have improved oral disintegration properties, so they have a good texture and are easy to take.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004528854A JPWO2004016262A1 (ja) | 2002-08-12 | 2003-08-08 | アミノ酸含有チュアブル錠 |
EP03788067A EP1541140A1 (en) | 2002-08-12 | 2003-08-08 | Amino acid-containing chewable |
US10/522,946 US20060039967A1 (en) | 2002-08-12 | 2003-08-08 | Amino acid-containing chewable |
AU2003254914A AU2003254914A1 (en) | 2002-08-12 | 2003-08-08 | Amino acid-containing chewable |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002235160 | 2002-08-12 | ||
JP2002-235160 | 2002-08-12 | ||
JP2002-375397 | 2002-12-25 | ||
JP2002375397 | 2002-12-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004016262A1 true WO2004016262A1 (ja) | 2004-02-26 |
Family
ID=31890522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/010181 WO2004016262A1 (ja) | 2002-08-12 | 2003-08-08 | アミノ酸含有チュアブル錠 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060039967A1 (ja) |
EP (1) | EP1541140A1 (ja) |
JP (1) | JPWO2004016262A1 (ja) |
AU (1) | AU2003254914A1 (ja) |
WO (1) | WO2004016262A1 (ja) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005298373A (ja) * | 2004-04-08 | 2005-10-27 | Kyowa Hakko Kogyo Co Ltd | 吸水性アミノ酸含有糖衣錠剤 |
WO2005105047A1 (en) | 2004-04-30 | 2005-11-10 | Quantum Hi-Tech (Beijing) Research Institute | Orally disintegrating tablet and method of preparation |
WO2006090640A1 (ja) * | 2005-02-23 | 2006-08-31 | Taiyokagaku Co., Ltd. | アミノ酸含有錠剤組成物および錠剤の製造方法 |
JP2010132626A (ja) * | 2008-12-08 | 2010-06-17 | Kyorin Pharmaceut Co Ltd | 口腔内速崩壊性錠剤 |
US7867499B2 (en) | 2004-11-05 | 2011-01-11 | Novartis Ag | Methods of treating dementia by administering virus-like particles coupled to Aβ |
JP2011250768A (ja) * | 2010-06-04 | 2011-12-15 | Terumo Corp | 分岐鎖アミノ酸含有総合栄養食品 |
JP2012121925A (ja) * | 2005-01-31 | 2012-06-28 | Kyowa Hakko Bio Co Ltd | オルニチン塩酸塩を含有する錠剤 |
JP2013087074A (ja) * | 2011-10-17 | 2013-05-13 | Daido Kasei Kogyo Kk | 医薬用結合剤及び該結合剤を用いた製剤 |
JP2013193974A (ja) * | 2012-03-19 | 2013-09-30 | Fancl Corp | アミノ酸高含有錠剤 |
JP2013223483A (ja) * | 2012-03-19 | 2013-10-31 | Fancl Corp | 高分岐環状構造を持つデキストリンを含有するアミノ酸高含有錠剤 |
WO2017170763A1 (ja) * | 2016-04-01 | 2017-10-05 | 株式会社クレハ | 崩壊錠及びその製造方法 |
JP2019507670A (ja) * | 2016-02-23 | 2019-03-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | グリシン粒子 |
JP2019052147A (ja) * | 2017-09-13 | 2019-04-04 | 大原薬品工業株式会社 | 化学的な安定性が改善された、プレガバリン含有口腔内崩壊錠 |
JP2022001602A (ja) * | 2017-09-25 | 2022-01-06 | 花王株式会社 | 圧縮成型製剤 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017001749A2 (pt) | 2014-07-30 | 2017-11-21 | Merck Patent Gmbh | tipos de álcool polivinílico em pó, diretamente comprimíveis |
ES2774359T3 (es) * | 2014-07-30 | 2020-07-20 | Merck Patent Gmbh | Composición que puede comprimirse directamente que contiene celulosa microcristalina |
BR112017001758A2 (pt) * | 2014-07-30 | 2017-11-21 | Merck Patent Gmbh | álcoois polivinílicos diretamente compressíveis |
US20190022013A1 (en) | 2015-12-19 | 2019-01-24 | First Time Us Generics Llc | Soft-chew tablet pharmaceutical formulations |
CN108712900A (zh) | 2015-12-19 | 2018-10-26 | 第时间美国泛型药物有限公司 | 软咀嚼片剂药物制剂 |
US11350657B2 (en) * | 2018-08-06 | 2022-06-07 | Pharmavite, Llc | Protein gummy composition |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000007555A (ja) * | 1998-04-23 | 2000-01-11 | Nitto Yakuhin Kogyo Kk | 錠剤およびこの錠剤の製造方法 |
JP2000095707A (ja) * | 1998-09-22 | 2000-04-04 | Rohto Pharmaceut Co Ltd | 苦味を有する薬物を含有する口中溶解型又は咀嚼型固形内服医薬組成物 |
JP2001169752A (ja) * | 1999-12-15 | 2001-06-26 | Fancl Corp | 食品組成物 |
JP2002003372A (ja) * | 2000-06-20 | 2002-01-09 | Ajinomoto Co Inc | 造血および栄養状態改善用アミノ酸組成物 |
JP2003221327A (ja) * | 2002-01-25 | 2003-08-05 | Ajinomoto Co Inc | 分岐鎖アミノ酸含有チュアブル剤 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO984B1 (en) * | 1977-10-11 | 1979-12-01 | بيتشام غروب ليمتد | A dry pharmaceutical compound with a suitable dosage unit for oral administration |
DE69331839T2 (de) * | 1992-01-29 | 2002-12-12 | Takeda Chemical Industries Ltd | Schnellösliche Tablette und ihre Herstellung |
US5607697A (en) * | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
DK0922464T3 (da) * | 1996-07-12 | 2005-06-06 | Daiichi Seiyaku Co | Hurtigt desintegrerbare, kompressionsstöbte materialer og fremgangsmåder til fremstilling af samme |
JPH10182436A (ja) * | 1996-10-31 | 1998-07-07 | Takeda Chem Ind Ltd | 固形医薬製剤 |
US5958453A (en) * | 1996-10-31 | 1999-09-28 | Takeda Chemical Industries, Ltd. | Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility |
JP2000007556A (ja) * | 1998-06-22 | 2000-01-11 | Lion Corp | チュアブル錠 |
GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
WO2003041698A1 (fr) * | 2001-11-13 | 2003-05-22 | Kyowa Hakko Kogyo Co., Ltd. | Comprimes contenant des acides amines se desintegrant rapidement dans la cavite buccale et procede de fabrication de ces comprimes |
US20060159759A1 (en) * | 2003-03-06 | 2006-07-20 | Kyowa Hakko Kogyo Co., Ltd | Tablet containing water-absorbing amino acid |
-
2003
- 2003-08-08 WO PCT/JP2003/010181 patent/WO2004016262A1/ja active Application Filing
- 2003-08-08 US US10/522,946 patent/US20060039967A1/en not_active Abandoned
- 2003-08-08 EP EP03788067A patent/EP1541140A1/en not_active Withdrawn
- 2003-08-08 JP JP2004528854A patent/JPWO2004016262A1/ja active Pending
- 2003-08-08 AU AU2003254914A patent/AU2003254914A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000007555A (ja) * | 1998-04-23 | 2000-01-11 | Nitto Yakuhin Kogyo Kk | 錠剤およびこの錠剤の製造方法 |
JP2000095707A (ja) * | 1998-09-22 | 2000-04-04 | Rohto Pharmaceut Co Ltd | 苦味を有する薬物を含有する口中溶解型又は咀嚼型固形内服医薬組成物 |
JP2001169752A (ja) * | 1999-12-15 | 2001-06-26 | Fancl Corp | 食品組成物 |
JP2002003372A (ja) * | 2000-06-20 | 2002-01-09 | Ajinomoto Co Inc | 造血および栄養状態改善用アミノ酸組成物 |
JP2003221327A (ja) * | 2002-01-25 | 2003-08-05 | Ajinomoto Co Inc | 分岐鎖アミノ酸含有チュアブル剤 |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005298373A (ja) * | 2004-04-08 | 2005-10-27 | Kyowa Hakko Kogyo Co Ltd | 吸水性アミノ酸含有糖衣錠剤 |
WO2005105047A1 (en) | 2004-04-30 | 2005-11-10 | Quantum Hi-Tech (Beijing) Research Institute | Orally disintegrating tablet and method of preparation |
EP1803446A1 (en) * | 2004-04-30 | 2007-07-04 | Quantum Hi-Tech (Beijing) Research Institute | Orally disintegrating tablet and method of preparation |
EP1803446A4 (en) * | 2004-04-30 | 2010-09-22 | Quantum Hi Tech Beijing Res In | MOUTH-CATCHING TABLET AND MANUFACTURING PROCESS |
US7867499B2 (en) | 2004-11-05 | 2011-01-11 | Novartis Ag | Methods of treating dementia by administering virus-like particles coupled to Aβ |
JP2012121925A (ja) * | 2005-01-31 | 2012-06-28 | Kyowa Hakko Bio Co Ltd | オルニチン塩酸塩を含有する錠剤 |
WO2006090640A1 (ja) * | 2005-02-23 | 2006-08-31 | Taiyokagaku Co., Ltd. | アミノ酸含有錠剤組成物および錠剤の製造方法 |
JP2010132626A (ja) * | 2008-12-08 | 2010-06-17 | Kyorin Pharmaceut Co Ltd | 口腔内速崩壊性錠剤 |
JP2011250768A (ja) * | 2010-06-04 | 2011-12-15 | Terumo Corp | 分岐鎖アミノ酸含有総合栄養食品 |
JP2013087074A (ja) * | 2011-10-17 | 2013-05-13 | Daido Kasei Kogyo Kk | 医薬用結合剤及び該結合剤を用いた製剤 |
JP2013193974A (ja) * | 2012-03-19 | 2013-09-30 | Fancl Corp | アミノ酸高含有錠剤 |
JP2013223483A (ja) * | 2012-03-19 | 2013-10-31 | Fancl Corp | 高分岐環状構造を持つデキストリンを含有するアミノ酸高含有錠剤 |
JP2019507670A (ja) * | 2016-02-23 | 2019-03-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | グリシン粒子 |
JP7137479B2 (ja) | 2016-02-23 | 2022-09-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | グリシン粒子 |
WO2017170763A1 (ja) * | 2016-04-01 | 2017-10-05 | 株式会社クレハ | 崩壊錠及びその製造方法 |
JPWO2017170763A1 (ja) * | 2016-04-01 | 2019-01-10 | 株式会社クレハ | 崩壊錠及びその製造方法 |
JP2019052147A (ja) * | 2017-09-13 | 2019-04-04 | 大原薬品工業株式会社 | 化学的な安定性が改善された、プレガバリン含有口腔内崩壊錠 |
JP2022001602A (ja) * | 2017-09-25 | 2022-01-06 | 花王株式会社 | 圧縮成型製剤 |
JP2022001601A (ja) * | 2017-09-25 | 2022-01-06 | 花王株式会社 | 圧縮成型製剤 |
JP2022003093A (ja) * | 2017-09-25 | 2022-01-11 | 花王株式会社 | 圧縮成型製剤 |
JP7167286B2 (ja) | 2017-09-25 | 2022-11-08 | 花王株式会社 | 圧縮成型製剤 |
JP7167288B2 (ja) | 2017-09-25 | 2022-11-08 | 花王株式会社 | 圧縮成型製剤 |
JP7167287B2 (ja) | 2017-09-25 | 2022-11-08 | 花王株式会社 | 圧縮成型製剤 |
Also Published As
Publication number | Publication date |
---|---|
AU2003254914A1 (en) | 2004-03-03 |
EP1541140A1 (en) | 2005-06-15 |
JPWO2004016262A1 (ja) | 2005-12-02 |
US20060039967A1 (en) | 2006-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004016262A1 (ja) | アミノ酸含有チュアブル錠 | |
US5753254A (en) | Therapeutic agents containing thyroid hormones | |
JP2546068B2 (ja) | L−カルニチン含有製剤 | |
US20090169682A1 (en) | Functional Masticatory Material, Method Of Producing The Same And Method Of Using The Same | |
US9339483B2 (en) | Amino-acid-containing medicinal granular preparation highly easy to take | |
JP4108605B2 (ja) | アミノ酸含有口腔内速崩壊錠及びその製造方法 | |
EP1604659B1 (en) | Tablet containing water-absorbing amino acid | |
CN107625786A (zh) | 一种碳酸钙维生素d3组合物及其无水吞服颗粒 | |
JP4689468B2 (ja) | 錠剤およびその製造方法 | |
WO2012001977A1 (ja) | 崩壊性組成物及び易崩壊性圧縮成型物 | |
JP2004242509A (ja) | コエンザイムq10およびアミノ酸類を含有する食品 | |
ITBO20120226A1 (it) | Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso. | |
JP2018525338A (ja) | オルニチンアスパルテートの発泡性配合物 | |
JP2004269384A (ja) | 吸水性アミノ酸被覆顆粒 | |
JP2005298373A (ja) | 吸水性アミノ酸含有糖衣錠剤 | |
JP6554034B2 (ja) | カルシウム剤 | |
EP1738755B1 (en) | Tablet containing branched chain amino acid and process for producing the same | |
JP2022098308A (ja) | アスパラギン酸又はその塩を主成分とする粉粒体経口組成物 | |
JP7167286B2 (ja) | 圧縮成型製剤 | |
JP7257715B2 (ja) | 経口組成物 | |
WO2008041740A1 (en) | Glutathione preparation and method for production thereof | |
JP2008086947A (ja) | 乾燥剤 | |
JP2004161700A (ja) | システイン類の苦味及び臭気が軽減された組成物 | |
JP2022174474A (ja) | 固形組成物 | |
JP2023082066A (ja) | 経口組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AU AZ BA BB BR BY BZ CA CN CO CR CU DM DZ EC GD GE HR ID IL IN IS JP KG KR KZ LC LK LR LT LV MA MD MG MK MN MX NI NO NZ OM PG PH PL RU SC SG SY TJ TM TN TT UA US UZ VC VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003788067 Country of ref document: EP Ref document number: 2004528854 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2006039967 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10522946 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2003788067 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10522946 Country of ref document: US |